BlackBarn Capital Partners LP In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), BlackBarn Capital Partners LP reported 11 stock positions worth $278.9 million . Its top holding was Roivant Sciences (ROIV) at 24.0% of the portfolio, followed by Diversified Healthcare Trust (DHC, 11.4% ) and Privia Health (PRVA, 11.1% ). Compared with Q3 2025, it opened 1 new position, sold out of 5, added to 6 and reduced 4. The biggest buy was a new position in Niq Global Intelligence (NIQ) and the biggest sale an exit from Nextpower (NXT).
Location NEW YORK, NY
CIK 0002010204
Portfolio Value $278.9M (Q4 2025) Holdings 11 stocks · $278.9M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q3 2025 ROIV Roivant Sciences Ltd. 3,084,300 $66.9M Reduce -29.9% DHC Diversified Healthcare Trust 6,530,140 $31.7M Add +6.2% PRVA Privia Health Group Inc. 1,300,000 $30.8M Add +19.2% NIQ Niq Global Intelligence PLC 1,800,000 $29.7M New NEE Nextera Energy Inc. 335,000 $26.9M Add +24.1% MH McGraw Hill Inc. 1,400,000 $23.1M Add +64.6% AMRX Amneal Pharmaceuticals Inc. 1,570,000 $19.8M Reduce -28.3% VKTX Viking Therapeutics Inc. 550,000 $19.3M Add +10.0% CCOI Cogent Communications Holdin 650,000 $14.0M Add +73.3% ABUS Arbutus Biopharma Corp. 1,850,000 $8.9M Reduce -7.5% ACLS Axcelis Technologies Inc. 96,573 $7.8M Reduce -51.7%
Options reported separately and not counted above: SPY puts ($1.0B), RMD puts ($96.3M), WRBY puts ($65.4M), ELAN puts ($38.5M), OSCR puts ($18.7M).
Portfolio Sells Q3 2025 → Q4 2025 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2025 % Of Portfolio Change To Portfolio ▲ NXT Nextpower Inc. Sold out 0.00% −8.45 TEVA Teva Pharmaceutical-SP ADR Sold out 0.00% −6.59 MOH Molina Healthcare Inc. Sold out 0.00% −5.93 ACLS Axcelis Technologies Inc. Reduce -51.7% 2.78% −3.59 FBLA FB Bancorp Inc. Sold out 0.00% −2.45 BVFL BV Financial Inc. Sold out 0.00% −1.53 AMRX Amneal Pharmaceuticals Inc. Reduce -28.3% 7.09% −0.06 ABUS Arbutus Biopharma Corp. Reduce -7.5% 3.19% +0.23 ROIV Roivant Sciences Ltd. Reduce -29.9% 24.00% +2.27
Portfolio Buys Q3 2025 → Q4 2025 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2025 % Of Portfolio Change To Portfolio ▼ NIQ Niq Global Intelligence PLC New 10.64% +10.64 MH McGraw Hill Inc. Add +64.6% 8.28% +4.80 NEE Nextera Energy Inc. Add +24.1% 9.64% +2.99 VKTX Viking Therapeutics Inc. Add +10.0% 6.94% +2.65 DHC Diversified Healthcare Trust Add +6.2% 11.36% +2.50 PRVA Privia Health Group Inc. Add +19.2% 11.05% +2.19 CCOI Cogent Communications Holdin Add +73.3% 5.02% +0.33
Options Activity Q3 2025 → Q4 2025 Security Type Change vs Q3 2025 Underlying Shares Value ▼ SPY SS SPDR S&P 500 ETF Trust-US put Add +20.0% 1,500,000 $1.0B RMD Resmed Inc. put Reduce -42.9% 400,000 $96.3M WRBY Warby Parker Inc. Class A put Add +200.0% 3,000,000 $65.4M ELAN Elanco Animal Health Inc. put Add +126.7% 1,700,000 $38.5M OSCR Oscar Health Inc. Class A put Add +4.0% 1,300,000 $18.7M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 17 $402.2M ROIV, PRVA, DHC, NEE, NIQ Q1 2026 14 $332.4M ROIV, VECO, PRVA, DHC, NEE Q4 2025 11 $278.9M ROIV, DHC, PRVA, NIQ, NEE Q3 2025 15 $306.4M ROIV, PRVA, DHC, NXT, AMRX Q2 2025 20 $301.8M ROIV, AMRX, ACLS, DHC, MOH Q1 2025 18 $292.8M ROIV, UNH, MOH, AMRX, ACLS Q4 2024 15 $254.1M ROIV, UNH, MOH, TEVA, AMRX Q3 2024 18 $230.1M ROIV, MOH, AMRX, DHC, T Q2 2024 17 $194.0M ROIV, UNH, MOH, AMRX, BRBS Q1 2024 21 $173.0M ROIV, MOH, UNH, CHRD, CF